• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5071034)   Today's Articles (71)
For: Van Tassell BW, Munger MA. Aliskiren for Renin Inhibition: A New Class of Antihypertensives. Ann Pharmacother 2016;41:456-64. [PMID: 17341529 DOI: 10.1345/aph.1h549] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
Number Cited by Other Article(s)
1
Kakar P, Lip GYH. Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. Expert Rev Cardiovasc Ther 2014;5:441-50. [PMID: 17489669 DOI: 10.1586/14779072.5.3.441] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
2
Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. Clin Exp Nephrol 2013;18:821-30. [DOI: 10.1007/s10157-013-0914-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2013] [Accepted: 11/08/2013] [Indexed: 11/26/2022]
3
Irons BK, Trujillo A, Seifert CF, Simoni JS, Doctolero S, Abo-Salem E, Meyerrose GE. Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus. J Cardiovasc Pharmacol Ther 2013;18:427-32. [PMID: 23695772 DOI: 10.1177/1074248413489772] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
4
Bonanni L, Dalla Vestra M. Oral renin inhibitors in clinical practice: a perspective review. Ther Adv Chronic Dis 2012;3:173-181. [PMID: 23342233 PMCID: PMC3539287 DOI: 10.1177/2040622312446244] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
5
Rashikh A, Ahmad SJ, Pillai KK, Najmi AK. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases. J Pharm Pharmacol 2011;64:470-81. [DOI: 10.1111/j.2042-7158.2011.01414.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
6
Kunikullaya U K, Ananthakrishnan V, Goturu J. Robert Tigerstedt and the discovery of renin - a revisit. Int J Cardiol 2011;158:1-5. [PMID: 22133471 DOI: 10.1016/j.ijcard.2011.11.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2011] [Accepted: 11/04/2011] [Indexed: 11/29/2022]
7
Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J Mol Graph Model 2010;29:425-35. [DOI: 10.1016/j.jmgm.2010.08.003] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2010] [Revised: 08/09/2010] [Accepted: 08/17/2010] [Indexed: 11/21/2022]
8
Chaudhary K, Nistala R, Whaley-Connell A. Is there a future for direct renin inhibitors? Expert Opin Investig Drugs 2010;19:653-61. [DOI: 10.1517/13543781003781906] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
9
Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial. J Hum Hypertens 2009;24:600-8. [PMID: 20033075 DOI: 10.1038/jhh.2009.107] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
10
Fintel DJ. The role of RAS modification for primary and secondary stroke prevention. Postgrad Med 2009;121:115-22. [PMID: 19641277 DOI: 10.3810/pgm.2009.07.2037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
11
Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 2009;10:65-76. [DOI: 10.1177/1470320309104662] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
12
Baldwin CM, Plosker GL. Aliskiren/Hydrochlorothiazide Combination. Drugs 2009;69:833-41. [DOI: 10.2165/00003495-200969070-00004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
13
Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res 2009;32:169-75. [DOI: 10.1038/hr.2008.21] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
14
Maibaum J, Feldman DL. Chapter 5 Case History on Tekturna®/Rasilez® (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2009. [DOI: 10.1016/s0065-7743(09)04405-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
15
Triller DM, Evang SD, Tadrous M, Yoo BK. First renin inhibitor, aliskiren, for the treatment of hypertension. ACTA ACUST UNITED AC 2008;30:741-9. [PMID: 18802783 DOI: 10.1007/s11096-008-9252-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2007] [Accepted: 08/31/2008] [Indexed: 11/30/2022]
16
A Nonpeptide, Piperidine Renin Inhibitor Provides Renal and Cardiac Protection in Double-Transgenic Mice Expressing Human Renin and Angiotensinogen Genes. Cardiovasc Drugs Ther 2008;22:469-78. [DOI: 10.1007/s10557-008-6131-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2008] [Accepted: 07/17/2008] [Indexed: 11/25/2022]
17
Daugherty KK. Aliskiren. Am J Health Syst Pharm 2008;65:1323-32. [PMID: 18593678 DOI: 10.2146/ajhp070529] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]  Open
18
Fisher NDL, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117:3199-205. [PMID: 18559696 DOI: 10.1161/circulationaha.108.767202] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
19
Yokokawa F, Maibaum J. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543776.18.6.581] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
20
Hanessian S, Guesné S, Riber L, Marin J, Benoist A, Mennecier P, Rupin A, Verbeuren TJ, Nanteuil GD. Targeting ACE and ECE with dual acting inhibitors. Bioorg Med Chem Lett 2008;18:1058-62. [DOI: 10.1016/j.bmcl.2007.12.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2007] [Accepted: 12/06/2007] [Indexed: 01/23/2023]
21
Oh BH. Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives. Expert Opin Pharmacother 2007;8:2839-49. [PMID: 17956203 DOI: 10.1517/14656566.8.16.2839] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
22
Burnier M. Hypertension and the kidney: new avenues for an improved management of hypertension in renal diseases: introduction. Semin Nephrol 2007;27:509-10. [PMID: 17868786 DOI: 10.1016/j.semnephrol.2007.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
23
Mayhew M. New Drug Available for Treating Hypertension. J Nurse Pract 2007. [DOI: 10.1016/j.nurpra.2007.04.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
24
Frampton JE, Curran MP. Aliskiren. Drugs 2007;67:1767-92. [PMID: 17683174 DOI: 10.2165/00003495-200767120-00008] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA